FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis

The FDA has cleared Quantum BioPharma's investigational new drug (IND) application for Lucid-MS (Lucid-21-302), a first-in-class compound targeting demyelination, to advance the compound into a phase 2 trial in people with progressive multiple sclerosis (MS).¹

Trial start-up activities, including site selection, are underway, with patient enrollment expected to begin as quickly as possible. The planned phase 2 study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of Lucid-MS using clinical and radiological measures relevant to disability progression.^1,2

Quantum BioPharma is working with a clinical research organization to support trial implementation, and the company has named Salvatore Napoli, MD, president and medical director of the Neurology Center of New England and the MS Center of New England, as principal investigator.²

"The randomized, double-blind, placebo-controlled Phase 2 trial is intended to evaluate efficacy using clinical and radiological measures relevant to disability progression and disease biology, while also assessing safety and tolerability," Andrzej Chruscinski, MD, PhD, vice president of scientific and clinical affairs at Quantum BioPharma, said in a statement.¹

Supporting phase 1 data

The IND submission built on a phase 1 multiple ascending dose trial in 40 healthy volunteers aged 18 to 60, presented at the 2026 ACTRIMS Forum.³ Participants received oral Lucid-21-302 at 150 mg or 300 mg daily for 7 days, or placebo; the drug was generally well tolerated, with 38 treatment-emergent adverse events reported across 12 of 40 participants, most mild and none considered related to study drug.

All told, pharmacokinetic data showed dose-proportional exposure, with area-under-the-curve values rising from roughly 4.2-5.3 hr·µg/mL at the 150 mg dose to 9.8-11.6 hr·µg/mL at 300 mg.³ That trial followed the completion of 180-day repeated-dose oral toxicity and toxicokinetic studies in late 2025, which the company said supported both the IND application and the design of the phase 2 trial.⁴

Mechanism and background

Lucid-MS is a non-covalent inhibitor of protein arginine deiminase 2 (PAD2), an enzyme expressed in the central nervous system that catalyzes citrullination of myelin proteins.³ Unlike most currently approved MS therapies, which work by modulating the immune system, Lucid-MS is designed to act directly on the demyelination process; in preclinical models, the company has reported that the compound prevented and reversed myelin breakdown.^1,2

A history of setbacks in remyelination

No FDA-approved MS therapy currently has demonstrated remyelinating or demyelination-preventing properties, and the broader field has faced repeated setbacks. In late 2025, Contineum Therapeutics reported that PIPE-307, a muscarinic M1 receptor antagonist, failed to separate from placebo in VISTA (NCT06083753), a phase 2 proof-of-concept trial in relapsing-remitting MS, though the company said it planned to further examine the study's exploratory endpoints.⁵

Biogen's opicinumab, an anti-LINGO-1 monoclonal antibody designed to promote remyelination by blocking a negative regulator of oligodendrocyte maturation, missed its primary and secondary endpoints in the phase 2b SYNERGY trial, though a post hoc analysis suggested a possible dose-response signal in some subgroups.⁶ Biogen pursued a follow-up phase 2 trial, AFFINITY, but discontinued the entire opicinumab program in October 2020 after that study also failed to meet its main and secondary goals.⁷

REFERENCES
1. Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis. News release. Quantum BioPharma Ltd. August 10, 2026. Accessed August 12, 2026. https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html
2. Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis. News release. Quantum BioPharma Ltd. March 26, 2026. Accessed August 12, 2026. https://www.globenewswire.com/news-release/2026/03/26/3262941/0/en/Quantum-Biopharma-Announces-Appointment-of-Principal-Investigator-for-Planned-Phase-2-Clinical-Trial-of-Lucid-21-302-Lucid-MS-in-Multiple-Sclerosis.html
3. Chruscinski A, Joshi A, Stys P, Antel J, Kotra L. Results of a Phase 1 Multiple Ascending Dose Trial of Lucid-21-302 (Lucid-MS) in Healthy Volunteers: A Novel Myelin Protective Small Molecule to Prevent Disease Progression in Multiple Sclerosis. Presented at: 2026 ACTRIMS Forum; February 5-7, 2026; San Diego, CA. Abstract P131.
4. Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS). News release. Quantum BioPharma Ltd. December 23, 2025. Accessed August 12, 2026. https://finance.yahoo.com/news/quantum-biopharma-announces-completion-dosing-130000424.html
5. Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). News release. Contineum Therapeutics. November 20, 2025. Accessed August 12, 2026. https://ir.contineum-tx.com/news-releases/news-release-details/contineum-therapeutics-reports-topline-data-its-phase-2-pipe-307
6. Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(9):845-856. doi:10.1016/S1474-4422(19)30137-1
7. Biogen Inc. Form 8-K, Exhibit 99.1: Biogen Reports Third Quarter 2020 Results. US Securities and Exchange Commission. October 21, 2020. Accessed August 12, 2026. https://www.sec.gov/Archives/edgar/data/875045/000087504520000032/exhibit991-q32020press.htm